The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis

References

• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009;523–531.
   PubMedGoogle Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Surveillance Epidemiology and End Results. SEER stat fact sheets: chronic lymphocytic leukemia. Available from: http://seer.cancer.gov/statfacts/html/clyl.html
   Google Scholar
• Surveillance Epidemiology and End Results. SEER stat fact sheets: non-Hodgkin lymphoma. Available from: http://seer.cancer.gov/statfacts/html/nhl.html
   Google Scholar
• Surveillance Epidemiology and End Results. Fast stats. Available from: http://seer.cancer.gov/faststats/selections.php?series = cancer
   Google Scholar
• Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010;66:413–423.
   PubMed Web of Science ®Google Scholar
• Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309–317.
   PubMed Web of Science ®Google Scholar
• Treanda [package insert]. Frazer, PA: Teva Pharmaceutical Industries; 2012.
   Google Scholar
• Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21–27.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Gregory SA. Bendamustine's emerging role in the management of lymphoid malignancies. Semin Hematol 2011;48(Suppl. 1):S24–S36.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378–4384.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209–3216.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559–3566.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–210. Erratum in: J Clin Oncol 2008;26:1911.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106–114.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Rosing H, Darwish M, et al. Pharmacokinetics and excretion of (14)C-bendamustine in patients with relapsed or refractory malignancy. Drugs R D 2013;13:17–28.
   PubMedGoogle Scholar
• Dubbelman AC, Jansen RS, Rosing H, et al. Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine. Drug Metab Dispos 2012;40:1297–1307.
   PubMed Web of Science ®Google Scholar
• Owen JS, Melhem M, Passarell J, et al. Bendamustine pharmacokinetic profile and exposure response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010;66:1039–1049.
   PubMed Web of Science ®Google Scholar
• Preiss R, Teichert J, Pönisch W, et al. Bendamustine in patients with multiple myeloma and renal insufficiency. Onkologie 2003;26(Suppl. 5):S131, Abstract P717.
   Google Scholar
• Centers for Disease Control and Prevention. Prevalence of chronic kidney disease and associated risk factors--United States, 1999–2004. MMWR Morb Mortal Wkly Rep 2007;56:161–165.
   PubMedGoogle Scholar
• Stevens LA, Li S, Wang C, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010;55(Suppl. 2):S23–S33.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.02, 2009. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf
   Google Scholar
• Hosmer DW Jr, Lemeshow S. Applied survival analysis: regression modeling of time to event data. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2008.
   Google Scholar
• Ramasamy K, Hazel B, Mahmood S, et al. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011;155:632–634.
   PubMed Web of Science ®Google Scholar
• van der Jagt R, Laneuville P, Macdonald D, et al. A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Curr Oncol 2012;19:160–168.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin Oncol 2002;29(Suppl. 13):23–26.
   PubMed Web of Science ®Google Scholar
• Pönisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 2012;138:1405–1412.
   PubMed Web of Science ®Google Scholar